Alexandria Hammond's Stock Ratings

B of A Securities Analyst

Alexandria Hammond is an analyst at B of A Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/04/2025

Overall Average Return

-3.37%

Smart Score

47.2%

Overall Average Return Percentile

32nd

Number of Ratings

14
Buy NowGet Alert
01/30/2025AKROBuy Now
Akero Therapeutics
$44.8740.41%
Alexandria Hammond47%
$35 → $63UpgradeNeutral → BuyGet Alert
11/15/2024REGNBuy Now
Regeneron Pharmaceuticals
$605.1090.05%
Alexandria Hammond47%
→ $1150Initiates → OutperformGet Alert
11/15/2024PFEBuy Now
Pfizer
$24.183.39%
Alexandria Hammond47%
→ $25Initiates → UnderperformGet Alert
11/15/2024MRNABuy Now
Moderna
$27.4045.99%
Alexandria Hammond47%
→ $40Initiates → UnderperformGet Alert
11/15/2024MRKBuy Now
Merck & Co
$83.28—
Alexandria Hammond47%
—Initiates → Peer PerformGet Alert
11/15/2024LLYBuy Now
Eli Lilly
$825.0021.21%
Alexandria Hammond47%
→ $1000Initiates → OutperformGet Alert
11/15/2024JNJBuy Now
Johnson & Johnson
$156.1521.68%
Alexandria Hammond47%
→ $190Initiates → OutperformGet Alert
11/15/2024GILDBuy Now
Gilead Sciences
$103.686.1%
Alexandria Hammond47%
→ $110Initiates → OutperformGet Alert
11/15/2024BMYBuy Now
Bristol-Myers Squibb
$50.68—
Alexandria Hammond47%
—Initiates → Peer PerformGet Alert
11/15/2024BIIBBuy Now
Biogen
$123.53—
Alexandria Hammond47%
—Initiates → Peer PerformGet Alert
11/15/2024ABBVBuy Now
AbbVie
$199.033%
Alexandria Hammond47%
→ $205Initiates → OutperformGet Alert
04/22/2024AKROBuy Now
Akero Therapeutics
$44.87-33.14%
Alexandria Hammond47%
→ $30Reinstates → NeutralGet Alert
04/22/2024MDGLBuy Now
Madrigal Pharmaceuticals
$315.48-52.45%
Alexandria Hammond47%
→ $150Initiates → UnderperformGet Alert
04/22/2024ETNBBuy Now
89bio
$8.73243.64%
Alexandria Hammond47%
→ $30Assumes → BuyGet Alert